Legacy Healthcare
Emmanuel Baert is an experienced healthcare professional with a diverse background in market access, business management, and strategic advisory roles. Currently serving as Country Manager at Legacy Healthcare, Emmanuel Baert is responsible for managing early access and compassionate access programs, as well as market access strategies for the US and EMA. As a Board Advisor at Quibiotic, Emmanuel Baert provides insight on development strategies and market access in the field of antibiototherapy. Previous roles include Business Unit Manager at Melinta Therapeutics, where Emmanuel Baert established the first Hospital Business for the Menarini Group in France, and Deputy Operational Manager for Servier in Colombia and Peru, focusing on strategic support and KOL management. With extensive experience at LFB Biomedicament across multiple managerial roles in Latin America, and a doctorate in Immunology, Emmanuel Baert brings a wealth of knowledge to the healthcare sector.
This person is not in any teams
This person is not in any offices
Legacy Healthcare
Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications. Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families. Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.